Analytical Data
-
Gene name
CD300LF
- Application
-
Alternative Names
CD300f; CD300LF; NKIR; IGSF13; CLM1; CD300 Antigen Like Family Member F; CMRF35-Like Molecule 1; Immunoglobulin superfamily member 13; NK inhibitory receptor
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TDQ1
-
Expression Region
Thr20~Ser156
-
Molecular Weight
46kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD300LF is an immunoglobulin-like receptor belonging to the CD300 family, which plays a crucial role in modulating immune responses. It is primarily expressed on various immune cells, including dendritic cells, T cells, and B cells, where it contributes to the regulation of activation, proliferation, and cytokine production. Research has shown that CD300LF engages with specific ligands, influencing processes such as T cell polarization and inhibition of pro-inflammatory signaling pathways. Given its pivotal role in immune modulation, CD300LF has garnered interest as a potential therapeutic target in various diseases, including autoimmune disorders and cancer. The recombinant protein of CD300LF offers a valuable tool for further exploring its functional properties, understanding its interaction with ligands, and elucidating its downstream signaling mechanisms. By creating a recombinant form of CD300LF, researchers can facilitate structural studies, assess binding affinities, and evaluate its effects in clinical models. Such insights may pave the way for novel immunotherapeutic strategies aimed at fine-tuning immune responses for better disease management. Overall, the study of CD300LF and its recombinant protein form represents a promising avenue for advancing our understanding of immune regulation and enhancing therapeutic interventions.
